Latest News about AWKNF
Recent news which mentions AWKNF
Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
October 15, 2024
From Benzinga
Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
September 18, 2024
From Benzinga
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
April 17, 2024
From Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
From Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
From Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
From Benzinga
Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation
December 21, 2023
Tickers
AWKNF
From Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
From Benzinga
From Benzinga
U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
October 15, 2023
Tickers
AWKNF
From Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
From Benzinga
Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
September 06, 2023
Tickers
AWKNF
From Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
From Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
From Benzinga
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
July 11, 2023
From Benzinga
Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
July 05, 2023
Tickers
AWKNF
From Benzinga
Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement
June 15, 2023
Tickers
AWKNF
From Benzinga
Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism
June 12, 2023
Tickers
AWKNF
From Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
From Benzinga
Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
April 28, 2023
Tickers
AWKNF
From Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
From Benzinga
Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
April 19, 2023
Tickers
AWKNF
From Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
April 17, 2023
From Benzinga
Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership
April 14, 2023
Tickers
AWKNF
From Benzinga
EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility
March 19, 2023
Tickers
AWKNF
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.